Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study

Annals of Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles